Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See "Cautionary Note Regarding Forward-Looking Statements". You should review the "Risk Factors" section of our Annual Report for the fiscal year ended December 31, 2021 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

We are a robotics company dedicated to the development of an advanced robotics system that enables remote, real-time, pinpoint accurate firing of small arms and light weapons. Our advanced robotics system is able to achieve pinpoint accuracy regardless of the movement of the weapons platform or the target.

We were founded in 2014 as Unlimited Aerial Systems, LLP ("UAS LLP"), and until the consummation of the Share Exchange Agreement (as hereinafter defined), we were a developer and manufacturer of commercial unmanned aerial systems, or drones, with the goal of providing a superior Quadrotor aerial platform at an affordable price point in the law enforcement and first responder markets.

On March 9, 2020, we closed on the Share Exchange Agreement (the "Share Exchange Agreement"), pursuant to which Duke Robotics, Inc., a Delaware corporation ("Duke") became our majority-owned subsidiary (the "Share Exchange"). Such closing date is referred to as the "Effective Time." As a result of the Share Exchange, the Company adopted the business plan of Duke.

On April 29, 2020, we, Duke, and UAS Acquisition Corp., a Delaware corporation and our wholly-owned subsidiary ("UAS Sub"), executed an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which UAS Sub was to merge, upon the satisfaction of customary closing conditions, with and into Duke, with Duke surviving as our wholly-owned subsidiary (the "Short-Form Merger"). Pursuant to the Merger Agreement, we intended to acquire the remaining outstanding shares of Duke held by those certain Duke shareholders that did not participate in the Share Exchange. On June 25, 2020, Duke filed a Certificate of Merger with the State of Delaware, and consequently, Duke became our wholly-owned subsidiary and the Short-Form Merger was consummated.

Duke has a wholly-owned subsidiary, Duke Airborne Systems Ltd. ("Duke Israel"), which was formed under the laws of the State of Israel in March 2014 and became the sole subsidiary of Duke after its incorporation. Our mailing address is 10 HaRimon Street, Mevo Science and Industrial Park, Israel, 2069203, and our telephone number is 011-972-4-8124101.

Readers are cautioned that to date, we have generated limited revenues and have not yet begun meaningful commercialization efforts with respect to our products. We intend in the long-term to derive substantial revenues from the sales of our products as well as future models of other robots and our unmanned aerial system ("UAS") platforms for both military and civilian use, but there can be no assurance that we will be able to do so.

On January 29, 2021, we, through Duke Israel, and Elbit Systems Land Ltd., an Israeli corporation ("Elbit"), entered into a collaboration agreement (the "Collaboration Agreement") for the global marketing and sales, and the production and further development of our developed advanced robotic system mounted on an UAS, armed with lightweight firearms, which we market under the commercial name "TIKAD."

As of the date of this quarterly report, to date, we have not experienced any material impact on our financial condition and results of operations due to COVID-19, and we do not expect to experience any material impact on our overall liquidity positions and outlook as a result of the outbreak. Nevertheless, given that COVID-19 is still an ongoing event in different parts of the world, it is still not possible at this time to estimate the full impact that the COVID-19 pandemic, the continued spread of COVID-19, and any additional measures taken by governments, health officials or by us in response to such spread, could have on our business results of operations and financial condition.





                                       14





Critical Accounting Policies

Please see Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. In addition, reference is made to Part I, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation of our Annual Report on Form 10-K for the year ended December 31, 2021 (filed on March 7, 2022) with respect to our Critical Accounting Policies and Estimates. The main changes to our critical accounting policies and estimates since our Annual Report on Form 10-K for the year ended December 31, 2021, relates to convertible loans Derivative Liabilities and Fair Value of Financial Instruments.





Results of Operations

Comparison of the three months ended June 30, 2022 and 2021

Revenues. We did not generate any revenues during the three months ended June 30, 2022 and June 30, 2021.

Research and Development. Our research and development expenses for the three months ended June 30, 2022, amounted to $3,000, compared to $0 for the three months ended June 30, 2021. Our research and development expenses, for the three months ended June 30, 2022, consisted primarily of professional services.

General and Administrative. Our general and administrative expenses for the three months ended June 30, 2022, which consisted primarily of professional services, stock-based compensation expenses and legal expenses, amounted to $327,000, compared to $271,000 for the three months ended June 30, 2021. The increase in general and administrative expenses for the three months ended June 30, 2022 was mainly due to an increase in stock-based compensation of $51,000.

Financial Income (expense). For the three months ended June 30, 2022, we had financial income of $43,000 compared to financial expense of $147,000 for the three months ended June 30, 2021. The reason for the decrease in financial expense for the three months ended June 30, 2022, was mainly due to the decrease in interest expense related to our previously outstanding convertible loans which have been repaid or converted in full.

Net Loss. We incurred a net loss of $287,000 for the three months ended June 30, 2022 as compared to $418,000 for the three months ended June 30, 2021, for the reasons set forth above.

Comparison of the six months ended June 30, 2022 and 2021

Revenues. We did not generate any revenues during the six months ended June 30, 2022 . We had revenues of $500,000 for the six months ended June 30, 2021, which were derived from the Collaboration Agreement.

Research and Development. Our research and development expenses for the six months ended June 30, 2022, amounted to $9,000, compare to none for the six months ended June 30, 2021. Our research and development expenses, for the six months ended June 30, 2022, consisted primarily of professional services.

General and Administrative. Our general and administrative expenses for the six months ended June 30, 2022, which consisted primarily of professional services, stock-based compensation expenses and legal expenses, amounted to $658,000, compared to $433,000 for the six months ended June 30, 2021. The increase in general and administrative expenses for the six months ended June 30, 2022 was mainly due to an increase in stock-based compensation and professional services.

Other Income. For the six months ended June 30, 2021 we had other income of $132 resulting from waiver of consulting fees accrued by March 31, 2021.

Financial Income (expense). For the six months ended June 30, 2022, we had financial income of $11,000 compared to financial expense of $366,000 for the six months ended June 30, 2021. The reason for the decrease in financial expense for the six months ended June 30, 2022, was mainly due to the decrease in interest expense related to our previously outstanding convertible loans which have been repaid or converted in full.

Net Loss. We incurred a net loss of $656,000 for the six months ended June 30, 2022 as compared to a net loss of $167,000 for the six months ended June 30, 2021, for the reasons set forth above.





                                       15

Liquidity and Capital Resources

We had $3,154,000 in cash on June 30, 2022 versus $3,946,000 in cash at June 30, 2021. The reason for the decrease in our cash balance was due to the operating expenses describe above. Cash used in operations for the six months ended June 30, 2022 was $376,000 as compared to cash provided by operations of $152,000 for the six months ended June 30, 2021. The reason for the increase in cash used in operations is mainly related to the increase in the net loss and the decrease in expenses with respect to convertible loans and debentures, partially offset by an increase in stock-based compensation.

Net cash used in investing activities was $30,000 for the six months ended June 30, 2022, as compared to net cash used in financing activities of $0 for the six months ended June 30, 2021. The increase is related to investments in office improvements and lease deposit.

Net cash used in financing activities was $0 for the six months ended June 30, 2022, as compared to net cash used in financing activities of $3,689,000 for the six months ended June 30, 2021. The decrease is a result of proceeds from a private placement transaction we completed in May 2021 and the full repayment of a convertible loans in 2021.

On September 2, 2019, we executed a promissory note having a total principal amount of $35,000 bearing interest at a 6% per annum and maturing on September 2, 2021 (the "Promissory Note"). The Promissory Note was a non-recourse and carried no personal guarantees. In conjunction with the consummation of the Share Exchange, and as a condition thereof, on March 6, 2020, we entered into several Securities Exchange Agreements, on the same terms, to exchange the Promissory Note for 9,623,621 shares of our common stock, par value $0.0001 per share (the "Common Stock"). On May 18, 2021, we issued 54,019 shares of Common Stock of the Company, to several holders pursuant to the terms of the Security Exchange Agreements pursuant to which, such holders were entitled to an anti-dilution clause in the event that the Convertible Debentures were converted into shares of our Common Stock.

In connection with the Share Exchange, immediately prior to the Effective Time, we entered into several convertible loan agreements, on the same terms, in the aggregate amount of $965,000 (each, a "Convertible Loan Agreement"). The terms of the Convertible Loan Agreements required repayment of the borrowed amount by the one-year anniversary of the Effective Time, unless, at our discretion, and subject to its compliance with any and all terms of the material terms of the Convertible Loan Agreements, the term of such loans is extended for an additional twelve (12) month period. The terms of the Convertible Loan Agreements also provide that we may repay any portion of the remaining outstanding loan amount, without penalty, provided, however, that the Company provides the specific lender with three business days' written notice prior to such repayment, during which time the lender may elect to convert any or all of the outstanding loan amount into shares of common stock of the Company. The Convertible Loan Agreements bore simple interest at a rate equal to 15% per annum, payable on the 15th day of each calendar month. On December 9, 2020, we utilized our rights under the Convertible Loan Agreements and extended the terms of the loans for an additional twelve months. During May 2021, we repaid the full balance of the principal of the Convertible Loans in the amount of $835,000.

Also, in connection with the Share Exchange, we entered into securities exchange agreements (each, an "Exchange Agreement") with our outstanding debt, Alpha Capital Anstalt ("Alpha") and GreenBlock Capital LLC ("GBC") to respectively cancel existing debentures or debt in the total amount of $658,323 and in exchange issue new debentures in the aggregate amount of $400,000 and issue 698,755 and 65,198 shares of common stock to each of Alpha and GBC, respectively. The New Debentures matured three years from the Effective Date, bore interest at a rate of 8% per year and were only convertible into shares of the Company's common stock, at an original conversion price of $0.3740 (the "Original Conversion Price"); provided, however, that such Original Conversion Price shall be adjusted downward in the event that the Company, as applicable, sells or grants any options to purchase or sells or grants any right to reprice, or otherwise dispose or issues any common stock or common stock equivalents entitling any purchaser to acquire shares of the Company's common stock at an effective price per share that is lower than the Original Conversion Price (such issuance, a "Dilutive Event"). In the event of a Dilutive Event at any time from the Effective Time through the six (6) month anniversary of the Effective Time, any such adjustment shall occur immediately after the completion of such period. Subsequent to March 31, 2021, a portion of the Convertible Debentures, representing an aggregate amount of $110,614 (including interest) was converted into 295,759 shares of Common Stock. During May 2021, we prepaid the full balance of the principal and interest amount of the Convertible Debentures in the amount of $108,541.





                                       16

On May 11, 2021, we entered into Securities Purchase Agreements with eight (8) non-U.S. investors (the "Investors"), pursuant to which we, in a private placement offering (the "Offering"), agreed to issue and sell to the Investors an aggregate of: (i) 12,500,000 shares of our Common Stock at a price of $0.40 per share; and (ii) warrants (the "Warrants") to purchase 12,500,000 of our Common Stock. The Warrants are exercisable immediately and for a term of 18 months and have an exercise price of $0.40 per share. The aggregate gross proceeds from the Offering were approximately $5,000,000 and the Offering closed on May 11, 2021. On April 5, 2022, we entered into an agreement with the Investors pursuant to which we extended the term of the Warrants, which now expire on November 11, 2023. The fair value of the expected additional cash payments as of June 30, 2022 was estimated at $27.

In view of our cash balance following the above transactions, we anticipate that our cash balances will be sufficient to permit us to conduct our operations up to the end of 2023. We may also satisfy its liquidity through the sale of its securities, either in public or private transactions.

If we are unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned development, which could harm our business, financial condition and operating results. If we obtain additional funds by selling any of our equity securities or by issuing common stock to pay current or future obligations, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the Common Stock. If adequate funds are not available to us when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.

© Edgar Online, source Glimpses